Zydus receives USFDA final approval for Azithromycin for Oral Suspension USP

Capital Market 

has received the final approval from the USFDA to market for Oral Suspension USP (USRLD - Zithromax), 100 mg/5 and 200 mg/5

This medication contains Azithromycin, a macrolide antibiotic that fights bacteria.

It is used to treat different types of such as respiratory infections, skin infections, and This medication will not work for such as common cold, etc. The drug will be manufactured at the group's formulations manufacturing facility at Baddi.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, August 01 2018. 11:04 IST